Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
AstraZeneca
Mallinckrodt
QuintilesIMS
Fish and Richardson
Dow
Accenture
Chinese Patent Office
US Army

Generated: December 16, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR BEXAROTENE

« Back to Dashboard

Clinical Trials for Bexarotene

Trial ID Title Status Sponsor Phase Summary
NCT00003752 Bexarotene in Treating Patients With Metastatic Breast Cancer Completed Ligand Pharmaceuticals Phase 2 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Randomized phase II trial to study the effectiveness of bexarotene in treating patients who have metastatic breast cancer.
NCT00030589 Chemotherapy and Photodynamic Therapy in Treating Patients With Cutaneous T-Cell Lymphoma Unknown status Millennix Phase 2 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Photodynamic therapy uses light and drugs that make cancer cells more sensitive to light to kill cancer cells. Photosensitizing drugs, such as methoxsalen, are absorbed by cancer cells and, when exposed to light, become active and kill the cancer cells. Combining chemotherapy with photodynamic therapy may be an effective treatment for cutaneous T-cell lymphoma. PURPOSE: Randomized phase II trial to study the effectiveness of combining different doses of bexarotene with photodynamic therapy in treating patients who have stage IB or stage IIA cutaneous T-cell lymphoma.
NCT00030849 Bexarotene and Interferon Alfa in Treating Patients With Cutaneous T-Cell Lymphoma Completed National Cancer Institute (NCI) Phase 2 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Interferon alfa may interfere with the growth of cancer cells. Combining chemotherapy with interferon alfa may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combining bexarotene with interferon alfa in treating patients who have cutaneous T-cell lymphoma.
NCT00030849 Bexarotene and Interferon Alfa in Treating Patients With Cutaneous T-Cell Lymphoma Completed Memorial Sloan Kettering Cancer Center Phase 2 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Interferon alfa may interfere with the growth of cancer cells. Combining chemotherapy with interferon alfa may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combining bexarotene with interferon alfa in treating patients who have cutaneous T-cell lymphoma.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Bexarotene

Condition Name

Condition Name for Bexarotene
Intervention Trials
Lymphoma 7
Mycosis Fungoides 6
Cutaneous T-cell Lymphoma 5
Sezary Syndrome 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Bexarotene
Intervention Trials
Lymphoma, T-Cell, Cutaneous 14
Lymphoma 13
Lymphoma, T-Cell 13
Carcinoma, Non-Small-Cell Lung 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Bexarotene

Trials by Country

Trials by Country for Bexarotene
Location Trials
United States 166
Australia 10
United Kingdom 9
Israel 6
Canada 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Bexarotene
Location Trials
Texas 14
New York 11
Pennsylvania 11
California 9
Florida 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Bexarotene

Clinical Trial Phase

Clinical Trial Phase for Bexarotene
Clinical Trial Phase Trials
Phase 4 2
Phase 3 8
Phase 2/Phase 3 1
[disabled in preview] 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Bexarotene
Clinical Trial Phase Trials
Completed 25
Terminated 7
Active, not recruiting 5
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Bexarotene

Sponsor Name

Sponsor Name for Bexarotene
Sponsor Trials
Ligand Pharmaceuticals 10
National Cancer Institute (NCI) 6
M.D. Anderson Cancer Center 4
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Bexarotene
Sponsor Trials
Other 43
Industry 33
NIH 6
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
Farmers Insurance
Federal Trade Commission
Argus Health
Mallinckrodt
Dow
Cipla
Cerilliant
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.